Medical uses:

Cytalux is an FDA-approved optical imaging agent used to assist in the intraoperative identification of:

• Malignant lesions in adults with ovarian cancer.
• Malignant and non-malignant pulmonary lesions in adults with known or suspected lung cancer.

Recommended Dosage:

• Pregnancy Test: Perform a pregnancy test in women of reproductive age to confirm the absence of pregnancy before administering Cytalux.
• Supplement Discontinuation: Discontinue folate, folic acid, or folate-containing supplements 48 hours prior to Cytalux administration.
• Prophylaxis: Consider using antihistamines and/or anti-nausea medication to prevent infusion-related reactions.

Dosage for Adult Patients:

• Ovarian Cancer: Administer a single intravenous infusion of 0.025 mg/kg diluted in 250 mL of 5% dextrose injection over 60 minutes, using a dedicated infusion line, 1 to 9 hours before surgery.
• Lung Cancer: Administer a single intravenous infusion of 0.025 mg/kg diluted in 250 mL of 5% dextrose injection over 60 minutes, using a dedicated infusion line, 1 to 24 hours before surgery.

Warnings & Precautions

• Patients receiving Cytalux may experience adverse reactions such as vomiting, nausea, abdominal pain, dyspepsia, flushing, chest discomfort, hypersensitivity, and elevated blood pressure. These reactions can occur within 15 minutes of starting the infusion. Treatment with antihistamines or anti-nausea medication may be administered.
• If a patient develops an infusion reaction during the administration of Cytalux 3.2 mg injection, the infusion should be interrupted and treated with antihistamines and/or anti-nausea medication as clinically indicated. The infusion should be completed within a few hours of the initial administration.
• When using Pofalacianine for intraoperative fluorescence imaging to detect ovarian cancer and lung lesions, errors such as false negatives or positives may occur. Non-fluorescing tissue in the surgical field does not rule out the presence of ovarian cancer or lung lesions. Fluorescence may also be observed in normal tissues, including the lungs, bowel, kidneys, and lymph nodes, as well as in inflamed tissues.
• Due to its mechanism of action, Pofalacianine may cause fetal harm if administered to a pregnant woman. Women of reproductive age should use effective contraception to mitigate the potential risk to a fetus. Pregnancy status should be verified before starting treatment.
• There is no data on the presence of pafolacianine in human milk, its effects on a breastfed infant, or its impact on milk production. The benefits of breastfeeding should be weighed against the mother’s clinical need for this medication and any potential adverse effects on the breastfed infant from pafolacianine or the underlying maternal condition.
• Using the incorrect diluent to prepare the Pofalacianine infusion solution can lead to the aggregation of pafolacianine, which may cause infusion reactions such as vomiting, nausea, abdominal pain, or rash. Only 5% Dextrose Injection should be used to prepare this infusion solution. Avoid using any other diluents

Documentation & Availability :

Documents  required to import Cytalux  to India? 

Cytalux  can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:

• 2 ID proofs along with PAN card details along with attested scanned copies
• Valid doctor prescription scanned copy
• Doctor’s MCI number
• Doctor’s mobile number
• Patients diagnostic reports

How is the order confirmed? 

The order will be confirmed only after the receipt of:

• The above-mentioned documents and drug availability.
• Import permit if applicable.

Sourcing & Delivery:

The Rx4U team has extensive experience in sourcing Cytalux  from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.

 FAQ:

What is the Generic Name for the trade name drug Portrazza®?

The generic name for Portrazza® is Necitumumab.

What is the Manufacturer’s Name of Portrazza®?

Portrazza® is manufactured by Eli Lilly and Company.

Is Portrazza® approved by the FDA?

Yes, Portrazza® was approved by the FDA on November 24, 2015.

What is the dosage and form of Portrazza® supplied?

Portrazza® is supplied as an injection: 800 mg/50 mL (16 mg/mL) solution in a single-dose vial for intravenous administration.

Where to Buy Portrazza® Injection in India?

You can buy Portrazza (necitumumab) 800 mg/50 mL (16 mg/mL) by Eli Lilly and Company online from https://rx4u.in/

What are the most common side effects of Portrazza®?

The most common side effects of Portrazza® are rash and hypomagnesemia.

How much does Portrazza cost in India?

The cost of Portrazza in India can vary. To procure this medication authentically, you can order the drug on https://rx4u.in/

What are the storage conditions of Portrazza®?

Store Portrazza vials in a refrigerator at 2-8°C (36-46°F). Keep the vials in the outer carton to protect them from light. Avoid freezing or shaking the vial.

Is it safe to buy Portrazza® online in India?

Yes, you can safely buy Portrazza injection online from the Rx4u who can help facilitate the import of Portrazza through legal channels.

*Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.